Responses
Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
